Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of masupirdine for agitation in Alzheimer's disease dementia
2021-003405-22Phase 3Active
- Sponsor
- Suven Life Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masupirdine in Alzheimer's disease (AD) and agitation (3 arms), sponsored by Suven Life Sciences. Primary endpoint: Change in CMAI items score aligning to the IPA agitation criteria. Started Sep 2022; status: active.
02
Drugs
masupirdine
03
Conditions
Alzheimer's disease (AD)agitation
Beyond the preview
Go deeper on 2021-003405-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003405-22.